Close Menu
Home › Eli Lilly Opens Phase III Trial for RET Fusion-Positive Non-Small Cell Lung Cancer Drug

Eli Lilly Opens Phase III Trial for RET Fusion-Positive Non-Small Cell Lung Cancer Drug

Dec 11, 2019
|
staff reporter

NEW YORK – Eli Lilly announced on Wednesday that its Phase III LIBRETTO-431 trial for the initial treatment of advanced or metastatic RET fusion-positive non-small cell lung cancer (NSCLC) is now openly enrolling patients. Enrollment will be capped at 400 participants.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Jan
28
Featured Webinar

Comprehensive Profiling of Myeloid Malignancies with Reliable Detection of FLT3 and CEBPA

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.  

What's Popular?

In Cancer

  1. Biocartis, AstraZeneca Expand Lung Cancer Biomarker Study With Master Collaboration Agreement

  2. Myriad Genetics Files for FDA Approval of BRACAnalysis CDx for Lynparza in Prostate Cancer

  3. B Cell Gene Expression Profiling May Enable Cancer Immunotherapy CDx Test

    Premium

  4. Genetic Testing Challenges in Oncology: Patient Told Genetic Test was Negative Turns out to be MAP Carrier

  5. UK's NICE Will Not Recommend Osimertinib for Untreated Non-Small Cell Lung Cancer

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.